• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Sarepta Therapeutics Set to Join S&P MidCap 400

    5/29/24 5:48:00 PM ET
    $JNJ
    $SPGI
    $SRPT
    $SWAV
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Finance: Consumer Services
    Finance
    Get the next $JNJ alert in real time by email

    NEW YORK, May 29, 2024 /PRNewswire/ -- Sarepta Therapeutics Inc. (NASD: SRPT) will replace Shockwave Medical Inc. (NASD: SWAV) in the S&P MidCap 400 effective prior to the opening of trading on Monday, June 3. S&P 500 constituent Johnson & Johnson (NYSE:JNJ) is acquiring Shockwave Medical in a deal expected to be completed soon pending final closing conditions.

    Following is a summary of the changes that will take place prior to the open of trading on the effective date:

    Effective Date

    Index Name      

    Action

    Company Name

    Ticker

    GICS Sector

    June 3, 2024

    S&P MidCap 400

    Addition

    Sarepta Therapeutics

    SRPT

    Health Care

    June 3, 2024

    S&P MidCap 400

    Deletion

    Shockwave Medical

    SWAV

    Health Care

    For more information about S&P Dow Jones Indices, please visit www.spdji.com

    ABOUT S&P DOW JONES INDICES

    S&P Dow Jones Indices is the largest global resource for essential index-based concepts, data and research, and home to iconic financial market indicators, such as the S&P 500® and the Dow Jones Industrial Average®. More assets are invested in products based on our indices than products based on indices from any other provider in the world. Since Charles Dow invented the first index in 1884, S&P DJI has been innovating and developing indices across the spectrum of asset classes helping to define the way investors measure and trade the markets.

    S&P Dow Jones Indices is a division of S&P Global (NYSE:SPGI), which provides essential intelligence for individuals, companies, and governments to make decisions with confidence. For more information, visit www.spdji.com.

    FOR MORE INFORMATION:

    S&P Dow Jones Indices

    [email protected]

    Media Inquiries

    [email protected]

    Cision View original content:https://www.prnewswire.com/news-releases/sarepta-therapeutics-set-to-join-sp-midcap-400-302158643.html

    SOURCE S&P Dow Jones Indices

    Get the next $JNJ alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $JNJ
    $SPGI
    $SRPT
    $SWAV

    CompanyDatePrice TargetRatingAnalyst
    Sarepta Therapeutics Inc.
    $SRPT
    7/29/2025$22.00Underweight → Equal Weight
    Barclays
    Sarepta Therapeutics Inc.
    $SRPT
    7/29/2025$13.00Mkt Perform
    Bernstein
    Sarepta Therapeutics Inc.
    $SRPT
    7/29/2025$37.00Perform → Outperform
    Oppenheimer
    Sarepta Therapeutics Inc.
    $SRPT
    7/29/2025$24.00Underweight → Neutral
    Analyst
    Sarepta Therapeutics Inc.
    $SRPT
    7/29/2025$5.00Sell
    H.C. Wainwright
    Sarepta Therapeutics Inc.
    $SRPT
    7/28/2025$10.00Equal Weight → Underweight
    Barclays
    Sarepta Therapeutics Inc.
    $SRPT
    7/25/2025Neutral → Underweight
    Analyst
    Sarepta Therapeutics Inc.
    $SRPT
    7/24/2025$7.00Sell
    Citigroup
    More analyst ratings

    $JNJ
    $SPGI
    $SRPT
    $SWAV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Weinberger Mark A bought $147,220 worth of shares (1,000 units at $147.22) (SEC Form 4)

    4 - JOHNSON & JOHNSON (0000200406) (Issuer)

    12/12/24 5:27:36 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Chambers Michael Andrew bought $4,955,728 worth of shares (37,038 units at $133.80) (SEC Form 4)

    4 - Sarepta Therapeutics, Inc. (0000873303) (Issuer)

    8/20/24 8:00:04 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Jacoby Rebecca bought $8,971 worth of shares (69 units at $130.01), increasing direct ownership by 17% to 469 units (SEC Form 4)

    4 - S&P Global Inc. (0000064040) (Issuer)

    6/17/24 4:04:40 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    $JNJ
    $SPGI
    $SRPT
    $SWAV
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for AMONDYS 45 issued to SAREPTA THERAPS INC

    Submission status for SAREPTA THERAPS INC's drug AMONDYS 45 (SUPPL-8) with active ingredient CASIMERSEN has changed to 'Approval' on 07/11/2024. Application Category: NDA, Application Number: 213026, Application Classification: Labeling

    7/12/24 4:40:36 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    June 20, 2024 - FDA Expands Approval of Gene Therapy for Patients with Duchenne Muscular Dystrophy

    For Immediate Release: June 20, 2024 Today, the U.S. Food and Drug Administration expanded the approval of Elevidys (delandistrogene moxeparvovec-rokl), a gene therapy for the treatment of Duchenne muscular dystrophy (DMD) for ambulatory and non-ambulatory individuals 4 years of age and older with DMD with a confirmed mutation in the DMD gene.  Elevidys was previously approved under accelerated approval for amb

    6/20/24 5:24:42 PM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for VYONDYS 53 issued to SAREPTA THERAPS INC

    Submission status for SAREPTA THERAPS INC's drug VYONDYS 53 (SUPPL-11) with active ingredient GOLODIRSEN has changed to 'Approval' on 06/04/2024. Application Category: NDA, Application Number: 211970, Application Classification: Labeling

    6/5/24 4:41:31 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    $SPGI
    $SRPT
    $SWAV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Sarepta Therapeutics upgraded by Barclays with a new price target

    Barclays upgraded Sarepta Therapeutics from Underweight to Equal Weight and set a new price target of $22.00

    7/29/25 10:25:29 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bernstein initiated coverage on Sarepta Therapeutics with a new price target

    Bernstein initiated coverage of Sarepta Therapeutics with a rating of Mkt Perform and set a new price target of $13.00

    7/29/25 7:40:24 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sarepta Therapeutics upgraded by Oppenheimer with a new price target

    Oppenheimer upgraded Sarepta Therapeutics from Perform to Outperform and set a new price target of $37.00

    7/29/25 7:24:05 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    $SPGI
    $SRPT
    $SWAV
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Asia Pacific Petroleum Conference (APPEC) to Address Key Industry Issues Facing Global Energy Markets

    Premier energy summit set for September to focus on 'Navigating Trade, Technology and Transition" SINGAPORE, Aug. 15, 2025 /PRNewswire/ -- The 41st annual Asia Pacific Petroleum Conference (APPEC) by S&P Global – Asia's leading energy conference - will take place from September 8 to 11, 2025, at the Raffles City Convention Centre in Singapore. A cornerstone of the energy industry for the past 40 years, this premier gathering of close to 1,500 industry leaders, experts and executives across 65 countries aims to explore the evolving landscape of the oil and gas sector, discussin

    8/15/25 7:01:00 AM ET
    $SPGI
    Finance: Consumer Services
    Finance

    Twilio Set to Join S&P MidCap 400

    NEW YORK, Aug. 14, 2025 /PRNewswire/ -- Twilio Inc. (NYSE:TWLO) will replace Amedisys Inc. (NASD: AMED) in the S&P MidCap 400 effective prior to the opening of trading on Tuesday, August 19. S&P 500 and S&P 100 constituent UnitedHealth Group Inc. (NYSE:UNH) acquired Amedisys in a deal completed today. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector August 19, 2025 S&P MidCap 400 Addition Twilio TWLO Information Technology August 19, 2025 S&P MidCap 400 Deletion Amedisys AMED Health Care For more information about S&P Dow Jones Indices, please visit www.spdji

    8/14/25 6:08:00 PM ET
    $AMED
    $SPGI
    $TWLO
    Medical/Nursing Services
    Health Care
    Finance: Consumer Services
    Finance

    Sarepta Therapeutics Announces Advancement of siRNA Collaboration and Sale of Arrowhead Equity Investment

    - Safety review leading to dose escalation and achievement of first predetermined enrollment target in Phase 1/2 study of SRP-1003 for DM1 triggers $100 million milestone payment - Sarepta sells at least $174 million of Arrowhead common stock for cash proceeds, Arrowhead will redeem $50 million of stock from Sarepta to prefund half of $100 million milestone payment due to Arrowhead Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that it has sold 9,265,312 shares of common stock of Arrowhead Pharmaceuticals, Inc. ("Arrowhead") in a privately negotiated block trade. The Company expects to receive at least $174 million i

    8/13/25 4:12:00 PM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    $SPGI
    $SRPT
    $SWAV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Exec VP, CFO Wolk Joseph J exercised 16,820 shares at a strike of $101.87 and sold $2,975,571 worth of shares (16,820 units at $176.91) (SEC Form 4)

    4 - JOHNSON & JOHNSON (0000200406) (Issuer)

    8/18/25 6:19:14 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President, Market Intelligence Saha Saugata sold $1,122,240 worth of shares (2,000 units at $561.12), decreasing direct ownership by 39% to 3,150 units (SEC Form 4)

    4 - S&P Global Inc. (0000064040) (Issuer)

    8/12/25 4:01:41 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    President, S&P Global Mobility Tavernier Edouard sold $998,526 worth of shares (1,799 units at $555.00), decreasing direct ownership by 10% to 17,138 units (SEC Form 4)

    4 - S&P Global Inc. (0000064040) (Issuer)

    8/8/25 4:00:59 PM ET
    $SPGI
    Finance: Consumer Services
    Finance

    $JNJ
    $SPGI
    $SRPT
    $SWAV
    SEC Filings

    View All

    SEC Form 144 filed by Johnson & Johnson

    144 - JOHNSON & JOHNSON (0000200406) (Subject)

    8/15/25 3:57:38 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Sarepta Therapeutics Inc.

    8-K - Sarepta Therapeutics, Inc. (0000873303) (Filer)

    8/13/25 4:10:35 PM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Sarepta Therapeutics Inc.

    S-8 - Sarepta Therapeutics, Inc. (0000873303) (Filer)

    8/6/25 4:16:02 PM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $JNJ
    $SPGI
    $SRPT
    $SWAV
    Financials

    Live finance-specific insights

    View All

    Sarepta Therapeutics Announces Second Quarter 2025 Financial Results and Recent Corporate Developments

    ELEVIDYS shipments have resumed for ambulatory individuals living with Duchenne following notification from the U.S. Food and Drug Administration (FDA); continuing to work with FDA on safety labeling process and risk-mitigation approach for non-ambulatory individuals Net product revenues for the second quarter 2025 totaled $513.1 million, a 42% increase over the same quarter of the prior year Previously announced restructuring advancing as planned; on track to realize over $100 million in cost savings through the end of 2025 Multiple clinical data readouts and milestones expected in 2025 and into early 2026 to support siRNA franchise - FSHD, DM1, SCA2, and Huntington's Disease

    8/6/25 4:05:00 PM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Sarepta Therapeutics to Announce Second Quarter 2025 Financial Results

    Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report second quarter 2025 financial results after the Nasdaq Global Market closes on Wednesday, August 6, 2025. As announced on July 16, 2025, the Company will not be hosting a conference call to discuss results at this time. About Sarepta Therapeutics Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (Duchenne) and are building a robust portfolio of programs across muscle, central nervous system, and cardiac diseases. For more information, ple

    7/31/25 8:48:00 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bill Eager Appointed President of S&P Global Mobility and CEO Designate of Planned Standalone Public Company

    Edouard Tavernier to Transition to Strategic Advisor Role Through September 30, 2025Company Separately Reports Second Quarter 2025 Results; Conference Call Today at 8:30 a.m. EDTNEW YORK, July 31, 2025 /PRNewswire/ -- S&P Global (NYSE:SPGI) today announced the appointment of Bill Eager, Chief Executive Officer of CARFAX, as President of S&P Global Mobility ("Mobility"), effective August 15, 2025, and CEO designate upon completion of the previously announced planned separation of Mobility into a standalone public company. Mr. Eager succeeds Edouard Tavernier, who will remain with the Company as a strategic advisor through September 30, 2025, to support a smooth transition.

    7/31/25 7:17:00 AM ET
    $SPGI
    Finance: Consumer Services
    Finance

    $JNJ
    $SPGI
    $SRPT
    $SWAV
    Leadership Updates

    Live Leadership Updates

    View All

    Twilio Set to Join S&P MidCap 400

    NEW YORK, Aug. 14, 2025 /PRNewswire/ -- Twilio Inc. (NYSE:TWLO) will replace Amedisys Inc. (NASD: AMED) in the S&P MidCap 400 effective prior to the opening of trading on Tuesday, August 19. S&P 500 and S&P 100 constituent UnitedHealth Group Inc. (NYSE:UNH) acquired Amedisys in a deal completed today. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name       Action Company Name Ticker GICS Sector August 19, 2025 S&P MidCap 400 Addition Twilio TWLO Information Technology August 19, 2025 S&P MidCap 400 Deletion Amedisys AMED Health Care For more information about S&P Dow Jones Indices, please visit www.spdji

    8/14/25 6:08:00 PM ET
    $AMED
    $SPGI
    $TWLO
    Medical/Nursing Services
    Health Care
    Finance: Consumer Services
    Finance

    Kodiak Gas Services Set to Join S&P SmallCap 600

    NEW YORK, Aug. 1, 2025 /PRNewswire/ -- Kodiak Gas Services Inc. (NYSE:KGS) will replace NV5 Global Inc. (NASD: NVEE) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, August 06. Acuren Corp. (NYSE:TIC) is acquiring NV5 Global in a deal expected to be completed soon pending final conditions.  Following is a summary of the change that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector August 06, 2025 S&P SmallCap 600 Addition Kodiak Gas Services KGS Energy August 06, 2025 S&P SmallCap 600 Deletion NV5 Global NVEE Industrials For more information about S&P Dow Jones Indices, please v

    8/1/25 5:54:00 PM ET
    $KGS
    $NVEE
    $SPGI
    Natural Gas Distribution
    Utilities
    Other Consumer Services
    Consumer Discretionary

    Veracyte Set to Join S&P SmallCap 600

    NEW YORK, July 24, 2025 /PRNewswire/ -- Veracyte Inc. (NASD: VCYT) will replace Triumph Group Inc. (NYSE:TGI) in the S&P SmallCap 600 effective prior to the opening of trading on Tuesday, July 29. Warburg Pincus LLC and Berkshire Partners LLC will acquire Triumph Group in a deal expected to close soon, pending final closing conditions. Following is a summary of the changes that will take place prior to the open of trading on the effective date: Effective Date Index Name Action Company Name Ticker GICS Sector July 29, 2025 S&P SmallCap 600 Addition Veracyte VCYT Health Care July 29, 2025 S&P SmallCap 600 Deletion Triumph Group TGI Industrials For more information about S&P Dow Jones Indices,

    7/24/25 5:58:00 PM ET
    $SPGI
    $TGI
    $VCYT
    Finance: Consumer Services
    Finance
    Aerospace
    Industrials

    $JNJ
    $SPGI
    $SRPT
    $SWAV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Sarepta Therapeutics Inc.

    SC 13G/A - Sarepta Therapeutics, Inc. (0000873303) (Subject)

    11/13/24 10:27:59 AM ET
    $SRPT
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Johnson & Johnson

    SC 13G - JOHNSON & JOHNSON (0000200406) (Filed by)

    4/10/24 5:12:55 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by ShockWave Medical Inc. (Amendment)

    SC 13G/A - Shockwave Medical, Inc. (0001642545) (Subject)

    2/13/24 5:13:59 PM ET
    $SWAV
    Medical/Dental Instruments
    Health Care